Relief and NeuroRx zone in on type 2 alveolar cells in COVID-19 trial

3 June 2020

Swiss biotech Relief Therapeutics (SWX: RLF) and its US partner, NeuroRx, have announced the start of treatment of patients with RLF-100 at the University of Miami Miller School of Medicine.

This is part of a Phase IIb/III trial to assess RLF-100 as a treatment for acute respiratory distress syndrome (ARDS) in COVID-19 patients on mechanical ventilation.

"There is an urgent need for a treatment that can specifically protect type 2 alveolar cells and suppress excessive inflammation"RLF-100 is a patented formulation of aviptadil, a synthetic human vasoactive intestinal polypeptide, that targets alveolar type 2 cells in the lungs that could be the major target of the SARS-CoV-2 virus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK